Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07652138RecruitingPhase 1
RN1201 injection for newly diagnosed multiple myeloma
This trial tests a new drug called RN1201 as a first-line treatment for multiple myeloma, a blood cancer. The study aims to see if it is safe and effective for patients who have never been treated for this condition before.
Suzhou, JiangsuAges 18–70 - NCT07648823RecruitingEarly Phase 1
New radioactive treatment for recurrent brain tumors
This early-stage trial tests a new radioactive drug called [177Lu]Lu-XT771 injected directly into the brain cavity after glioblastoma surgery. It measures whether the drug is safe and helps slow tumor regrowth in patients whose cancer has come back after earlier treatments.
Beijing, Beijing MunicipalityAges 18–80 - NCT07647094RecruitingPhase 2
Chemotherapy plus immunotherapy for advanced squamous lung cancer
This trial tests a combination of three drugs—two chemotherapy medications (carboplatin and nab-paclitaxel) plus an immunotherapy drug (serplulimab)—as a first-line treatment for advanced squamous cell non-small cell lung cancer. The goal is to see if this combination works better than standard treatment and is safe for patients who haven't received prior systemic cancer treatment.
Quzhou, ZhejiangAges 18–75 - NCT06685978RecruitingPhase 3
Study of Xiangjurupining Capsule for Breast Lumps and Pain
This trial tests a Chinese herbal capsule (Xiangjurupining) for women with breast hyperplasia (non-cancerous breast lumps and pain). It aims to see if the capsule can safely reduce pain and improve symptoms over several menstrual cycles.
Beijing, Beijing MunicipalityAges 18–50 - NCT05072041Recruiting
Degradable chemo bead treatment for liver cancer
This trial studies a new type of “degradable” chemo bead delivered through a catheter to treat hepatocellular carcinoma (HCC). It aims to check safety and whether the treatment works when surgery or transplant is not an option.
Seoul, SeoulAges 19–79 - NCT06141460RecruitingPhase 1/Phase 2
Gene therapy trial for wet age-related macular degeneration
This trial tests a new gene therapy called RRG001 for people with the 'wet' form of age-related macular degeneration. It aims to treat leaky blood vessels in the eye that can cause vision loss, possibly reducing the need for frequent eye injections.
Tianjin, Tianjin MunicipalityAges 50 years+ - NCT07640425RecruitingPhase 1/Phase 2
Testing a new collagenase injection for Dupuytren's contracture
This study tests whether a new injectable enzyme called CNT201 can safely and effectively treat Dupuytren's contracture—a condition where fingers curl and can't straighten. The injection aims to break down the thick tissue cords causing the problem, without surgery.
Kippa-Ring, QueenslandAges 18–75 - NCT07640451RecruitingPhase 2
HRS-9821 inhalation treatment for moderate to severe COPD
This trial tests whether an inhaled medication called HRS-9821 can help people with moderate to severe COPD (chronic obstructive pulmonary disease) breathe better and reduce symptoms. You inhale the medication, and researchers will measure how well your lungs work and how you feel over time.
Shanghai, Shanghai MunicipalityAges 40–80 - NCT07641426RecruitingPhase 1/Phase 2
CID-103 Treatment for Kidney Transplant Rejection
This study tests an experimental drug called CID-103 to treat antibody-mediated rejection (ABMR), a type of immune response that damages transplanted kidneys. The drug targets immune cells that attack the transplant, and researchers hope it may help preserve kidney function and prevent transplant failure.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07643766RecruitingPhase 2
Testing ENV-294 for moderate-to-severe atopic dermatitis
This study tests whether a new medication called ENV-294 can help adults with moderate-to-severe atopic dermatitis (eczema) that hasn't responded well to other treatments. The trial will check if the drug reduces itching and skin inflammation safely.
Encinitas, CaliforniaAges 18 years+ - NCT07645924RecruitingPhase 3
Elismetrep for fast relief of migraine attacks
This trial tests a new oral medication called elismetrep (K-304) for quickly stopping migraine pain and other symptoms. If you have regular migraines, this could offer a new option that works fast when a migraine starts.
Birmingham, AlabamaAges 18–75 - NCT07644832RecruitingPhase 1/Phase 2
New Blood-Clotting Injection for Hemophilia and Factor VII Deficiency
This early-stage trial tests a new injectable medicine called SR604 designed to help people with hemophilia A, hemophilia B, or congenital Factor VII deficiency—conditions where the blood doesn't clot properly. The study will look at how safe the medicine is and whether it reduces bleeding episodes.
ChangshaAges 18–65 - NCT04787042RecruitingPhase 1/Phase 2
Safety and early benefits of ST-067 for advanced solid tumors
This early-stage trial tests ST-067 to see if it is safe and whether it may shrink advanced cancers. It also looks at how the drug moves through the body and affects the immune system.
Scottsdale, ArizonaAges 18 years+ - NCT06557369Recruiting
New light therapy for intermediate age-related macular degeneration
This trial tests a new light-based treatment for intermediate age-related macular degeneration (AMD), a common eye condition that can lead to vision loss. The goal is to see if it is safe and helps slow down the disease.
BergamoAges 50 years+ - NCT06691555Recruiting
Long-term safety of a silicone tube eye implant
This study follows up with people who have previously received a special silicone tube implant in their eye to see how they are doing over time. It aims to check the long-term safety and how well the implant is working.
TbilisiAges 40–90 - NCT07638683RecruitingPhase 2
Teclistamab and Daratumumab for New Multiple Myeloma With Amyloidosis
This trial tests a combination of two newer cancer-fighting drugs (teclistamab and daratumumab) to treat people who have just been diagnosed with multiple myeloma—a blood cancer—and also have light chain amyloidosis, a condition where abnormal proteins build up in organs. The goal is to see if this combination works better and is safe for newly diagnosed patients.
ShanghaiAges 18 years+ - NCT07645690RecruitingEarly Phase 1
CD70 CAR-T Cell Therapy for Advanced Kidney Cancer
This early-stage trial tests a new type of cell therapy called CD70 CAR-T for advanced kidney cancer (clear cell renal cell carcinoma) that has spread or cannot be surgically removed. The therapy uses cells from your own immune system that are genetically modified to recognize and attack cancer cells.
BeijingAges 18–75 - NCT07644338Recruiting
Brain Stimulation for Post-Traumatic Stress Disorder
This study tests a new non-invasive brain stimulation technique called temporal interference stimulation to help reduce PTSD symptoms. If you have PTSD that's lasted at least 3 months, this trial may help you or contribute to better treatments for others.
ShanghaiAges 18–50 - NCT07638215Recruiting
Hydrogel for corneal wound repair
This study tests a new hydrogel glue that helps heal a damaged cornea (the clear front part of the eye) without needing stitches. It may help people with certain corneal defects from injury or after surgery.
Jinan, ShandongAges 18–85 - NCT06691152RecruitingPhase 1
CD19 UCAR T cells for severe lupus
This trial tests an experimental treatment called CD19 UCAR T cells for people with severe lupus that hasn't gotten better with standard medicines. It aims to see if these special immune cells can safely and effectively control the disease.
Hangzhou, ZhejiangAges 5 years+ - NCT05924100RecruitingPhase 2
Luspatercept for lower red blood counts in MDS with del5q
This Phase 2 trial studies luspatercept to improve anemia (low red blood cells) in people with MDS that has a del5q change. It also checks safety, especially for people who need red blood cell transfusions and have not benefited from prior standard treatments.
AlessandriaAges 18 years+ - NCT06681623Recruiting
Ublituximab in older adults with relapsing MS
This study is testing how safe and effective the medication ublituximab is for older adults (ages 55–80) with relapsing multiple sclerosis. It aims to see if this treatment works well for this age group.
Foxborough, MassachusettsAges 55–80 - NCT07633288RecruitingPhase 2
AP1189 Safety and Efficacy for Severe Respiratory Viral Infection
This trial tests whether an experimental drug called AP1189, added to standard hospital care, can help people hospitalized with severe breathing problems from viruses like COVID-19, flu, or RSV. The goal is to see if it reduces the need for mechanical ventilation or other life support.
Mostar, Herzegovina-Neretva CantonAges 18 years+ - NCT07632196Recruiting
Nerve Stimulation to Improve Bowel Control After Rectal Cancer Surgery
This trial tests whether a small electrical device placed on the skin behind your ankle can help improve bowel control after surgery to remove rectal cancer. Many patients experience changes in bowel function after this surgery, and this treatment may help restore normal continence.
Manresa, BarcelonaAges 18 years+
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,733 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.